5 Red Flags Before You Commercialize a Biological Product

A biological crop-protection product can look commercially exciting long before the evidence is strong enough for the next business decision. Strong efficacy data are important, but commercialization also depends on reproducibility, positioning, IPM fit, operational feasibility and whether the commercial claim is proportional to the evidence.

Five red flags to check before the next commercial step

One impressive trial is carrying the entire story.
Nobody can clearly explain the product's operating window.
The product has no clear job inside the IPM program.
The commercial claim is bigger than the evidence.
The product only works commercially on paper.

1. One impressive trial is carrying the entire story

A spectacular result can demonstrate biological potential. It does not automatically demonstrate commercial reliability.

The commercial question is not whether the product has ever produced excellent control. It is whether performance remains useful across the conditions that matter for the intended market: different trial dates, pest pressure, operators, production environments and increasingly realistic use conditions.

This is why weaker trials deserve attention rather than being treated as inconvenient noise. They may reveal the factor that controls performance: pest stage, temperature, humidity, crop architecture, application timing, coverage or another part of the use environment.

Decision test: separate the best result from the complete pattern of evidence. If one result carries the story, identify what additional evidence is needed before a larger commercial commitment.

2. Nobody can clearly explain the operating window

Every biological product has conditions under which it performs better and conditions under which performance becomes weaker. The problem is not having limitations. The problem is commercializing before those limitations are understood.

A useful operating window should translate the evidence into practical language. It should clarify the relevant pest stage, application timing, production conditions associated with success, and the circumstances that reduce reliability.

This information is commercially valuable. It improves positioning, technical recommendations, customer selection and trial design. A product that performs very well in a clearly defined use case can be more valuable than a product positioned broadly but used unpredictably.

Decision test: can the technical team explain where the product works best, where it becomes weaker and what the customer must do to reproduce successful use?

3. The product has no clear job inside the IPM program

A biological product does not enter an empty crop-protection system. Customers already have monitoring practices, pesticide programs, beneficial organisms, operational constraints and economic objectives.

The product therefore needs a clear job. Is it preventive? An early-intervention tool? A resistance-management option? A way to preserve beneficial organisms? A replacement for a particular treatment? A complementary option close to harvest?

"It controls the pest" is rarely enough to create a strong commercial position. A product with moderate direct efficacy can still be highly valuable if it improves the performance of the wider IPM program.

Decision test: describe the product's role in one sentence. If that sentence is unclear, the technical recommendation and commercial message are probably unclear too.

4. The commercial claim is bigger than the evidence

Commercial language can expand faster than the evidence. Results against one pest stage become a general pest claim. Greenhouse evidence becomes a field story. One crop becomes several crops. One region becomes a much larger market.

The more defensible direction is the opposite: start with the evidence and then define the claim it can support. A narrower claim can be commercially stronger when it is reproducible, technically defensible and easier for customers to use correctly.

For distributors and partners, this matters because an unsupported claim transfers risk downstream. Customer disappointment, technical complaints and retraining costs can become part of the distribution burden.

Decision test: create an evidence-to-claim table. For every important commercial claim, identify the evidence supporting it. If the link is weak, narrow the claim or generate the missing evidence.

5. The product only works commercially on paper

Biological efficacy is only one part of commercial feasibility. Storage, transport, shelf life, application timing, number of applications, equipment, water quality, operator training, technical support and total use cost can all affect whether customers can reproduce the conditions required for success.

A development team may operate under carefully controlled conditions. The commercial environment is less controlled. Products are transported, stored and applied by different people, often under time pressure.

The practical question is therefore simple: can a normal customer reproduce the conditions required for success without an unreasonable operational burden?

Decision test: follow the product from production to distributor to farm to application. Identify the points where biological performance can be lost or where the total value proposition becomes difficult to justify.

Turn the five red flags into a commercial decision

Not every evaluation needs to end with a simple yes or no. A more useful framework is:

Proceed. The evidence is strong enough for the next commercial step and the main limitations are understood.

Investigate further. The product is promising, but one or two evidence gaps could materially change the decision.

Do not proceed yet. The current evidence, positioning or operating model does not justify the next level of commitment.

The middle option is especially important. Resolving one critical uncertainty with a targeted study or evidence review can be much cheaper than scaling the wrong assumption.

Why this matters for biological product development

Regulatory efficacy frameworks also emphasize that efficacy should be evaluated for the intended use and that treatment timing, dose, application frequency and relevant conditions matter. EPPO maintains specific efficacy standards, including principles for microbial plant-protection products, while FAO guidance treats efficacy evaluation and data requirements as part of the evidence needed to support pesticide registration decisions.

A commercial decision is not identical to a regulatory decision, but the underlying discipline is similar: define the intended use, understand the conditions behind performance and avoid extending conclusions beyond the supporting evidence.